AZ Targets Viral Oncolytics With Transgene Development Deal
Executive Summary
AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.
You may also be interested in...
Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic
The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.
Targovax Pivots Towards Oncolytic Viruses
Oncolytic virus-based therapies which act as immune activators will be the only candidates in the Norwegian biotech’s pipeline from now on.
Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration
Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.